Idenix Pharmaceuticals, Inc.
Corporate Headquarters
60 Hampshire Street
Cambridge
Massachusetts
02139
United States
Tel: 617-995-9800
Fax: 617-995-9801
Website: http://www.idenix.com/
About Idenix Pharmaceuticals, Inc.
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. Idenix is advancing a robust product pipeline in HCV treatment with programs in four different HCV drug classes. The company’s clinical candidates include IDX184, a liver-targeted nucleotide polymerase inhibitor, IDX320, a protease inhibitor and IDX375, a non-nucleoside polymerase inhibitor. Idenix also has a preclinical NS5A inhibitor program. Idenix believes that the future of HCV treatment will include novel combinations of direct-acting antivirals (DAAs) which could eliminate the need for interferon and/or ribavirin. The company’s goal is to develop low dose, once- or twice-daily agents with broad genotypic activity, a low potential for drug-drug interaction and that are designed for use in multiple combination regimens. With programs that span the major HCV drug classes, Idenix is well positioned to build a combination drug development strategy, both internally and with partners, to advance the future HCV paradigm.234 articles about Idenix Pharmaceuticals, Inc.
-
Petrichor Names Preeminent Scientist and Biotechnology Industry Entrepreneur Dr. Raymond F. Schinazi to Advisory Board
7/24/2018
Petrichor Healthcare Capital Management today announced the appointment of Raymond F. Schinazi, PhD, DSc (Hon) to its Advisory Board.
-
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
-
Buyers Remorse: Merck & Co. Takes $2.9 Billion Charge on Hepatitis C Drug Inherited From $3.9 Billion Idenix Buy
2/27/2017
-
Merck & Co. Plans to Open Microbiome R&D Site in Former Idenix Facility in Cambridge
7/15/2016
-
Merck & Co., Inc. Completes Tender Offer To Acquire Idenix Pharmaceuticals, Inc.
8/5/2014
-
Idenix Pharmaceuticals, Inc. Reports Second Quarter And Six Month 2014 Financial Results
8/1/2014
-
Merck & Co., Inc. Begins Tender Offer To Acquire Idenix Pharmaceuticals, Inc.
6/20/2014
-
Merck & Co., Inc. Open To More Biotech Deals After Idenix Pharmaceuticals, Inc.: Research Chief
6/16/2014
-
AbbVie And Johnson & Johnson Were In A Bidding War For Idenix Pharmaceuticals, Inc., Will Achillion Pharmaceuticals, Inc. Be The Next Target?
6/13/2014
-
Merck & Co., Inc. Snags Cambridge's Idenix Pharmaceuticals, Inc. For $3.85 Billion
6/11/2014
-
Idenix Pharmaceuticals, Inc. Reports First Quarter 2014 Financial Results And HCV Pipeline Review
5/2/2014
-
Idenix Pharmaceuticals, Inc. To Present At Three Upcoming Healthcare Conferences
4/30/2014
-
Idenix Pharmaceuticals, Inc.'s "Good" News Shows Hep C Drug Market Increasingly Murky For Investors
4/9/2014
-
Idenix Pharmaceuticals, Inc. Announces Promising Clinical Data And Continued Progress In Nucleotide Prodrug Development Programs For The Treatment Of Hepatitis C
4/7/2014
-
Idenix Pharmaceuticals, Inc. Intends To Appeal Norway District Court Decision Regarding Patent Invalidity Case
3/24/2014
-
Idenix Pharmaceuticals, Inc. Announces Nucleotide Prodrug (IDX21437) And NS5A Inhibitor (Samatasvir) Poster Presentations At 49th Annual Meeting Of The European Association For The Study Of The Liver
3/24/2014
-
Idenix Pharmaceuticals, Inc. Files Patent Infringement Lawsuits Against Gilead Sciences, Inc. In Europe
3/14/2014
-
Idenix Pharmaceuticals, Inc. Reports Fourth Quarter And Year Ended 2013 Financial Results
2/28/2014
-
Idenix Pharmaceuticals, Inc. To Present At Two Upcoming Healthcare Conferences
2/26/2014
-
Idenix Pharmaceuticals, Inc. To Present At The 2014 Leerink Swann and Company Global Healthcare Conference
2/7/2014